Paris tech company scores FDA clearance for brain MRI assistant
French technology firm Qynapse recently received clearance from the U.S. Food and Drug Administration for a new software that assists radiologists in diagnosing brain diseases.
The QyScore program helps clinicians by pinpointing and quantifying brain atrophy and other MRI markers, which signal the early onset of conditions such as Alzheimer’s, Parkinson’s and multiple sclerosis. It also automatically generates patient reports in minutes, with results presented alongside a database of images from healthy patients, according to an announcement.
The Paris-based company previously earned CE mark approval for the program in 2017 and plans to roll out QyScore in the states soon.
“FDA clearance is a major milestone to expand the commercialization of the software within the U.S.,” CEO Olivier Courrèges said in a statement.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.